

Discover the benefits of replacing your TRACERlab™ MX/FX FDG with FASTlab™ 2 The cutting edge FASTlab 2 systems will keep you at the forefront of PET tracer production technology.

GE Healthcare offers dedicated guidance and support during your transition to an even more powerful synthesis platform.

You will continue to benefit from GE Healthcare enabling you to maintain high standards of PET tracer production well into the future.



STREAMLINE PRODUCTION OF ESSENTIAL TRACERS



CASSETTES

FDG Duo Citrate FLT NaF

FDG Citrate FMISO

Fully integrated plug-and-play cassettes with preloaded reagents*

- 2 minute set up, simply insert the cassette and go
- Validated by GE Healthcare to support GMP production
- FASTlab 2 Multi-Tracer accommodates new GE cassettes as they are developed

Ga-PSMA F-DOPA

CASSETTES

FET FES Ga-DOTA-TO

Versatile cassettes for tracer production*

Cassettes developed by third party*



* Customers should gain US Food and Drug Administration (FDA) approval for their tracers. FDA approval has been given for FDG and NaF tracers. Outside US approval depends on local regulation. FMISO, PSMA FLT, FDOPA, FET and FES are investigational agents not yet approved by regulatory authorities. FDG Duo cassettes only run on the FASTlab 2 platform. All other GE Multi-Tracer cassettes run on both FASTlab and FASTlab 2 platforms. FDOPA, FET and FES tracer applications are offered by third party-vendors. GE has no liability for third-party products. GE is not responsible for the availability of these tracer applications.



FUTUREPROOFING OUR FDG PRODUCTION CAPABILITIES

"FASTlab 2 has proven a robust and reliable platform, our uptime has been >99%."

"The transition from TRACERlab MX FDG modules to FASTlab 2 was seamless. Replacement of both our modules was completed within 7 business days, documented in our annual report to the FDA, and we have been using them to manufacture [18F]FDG for about one year already."



DELIVER ON PROMISES WITH MORE CONSISTENT SUPPLY




All FASTlab 2 FDG cassettes deliver high yield 1 with high reproducibility (± 4%)

- > 74% typical uncorrected yield
- > 85% typical decay-corrected yield


Validated by GE Healthcare to support GMP production

Yield independent of starting activity. Tested up to 25 Ci.
 Data from FDG phosphate cassette runs on FASTlab.
 GE Healthcare Commercial FDG Production, Eindhoven (The Netherlands), FASTlab 2011, TRACERlab FX FDG 2008. Université de Liège, (Belgium), TRACERlab MX, 1999.







TRACERIab MX¹



FASTIab¹ FDG phosphate









General Electric Company reserves the right to make changes in specifications and features shown herein, or discontinue the product described at any time without notice or obligation. Contact your GE Representative for the most current information.

© 2020 General Electric Company.

 ${\sf GE}, the\,{\sf GE}\,{\sf Monogram}, {\sf FASTIab}\,{\sf and}\,{\sf TRACERIab}\,{\sf are}\,{\sf trademarks}\,{\sf of}\,{\sf General}\,{\sf Electric}\,{\sf Company}.$

08-2020 JB61100XX(1)/PRT/OS

